July 17, 2019 — Abbott has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip heart valve repair device to treat mitral regurgitation. The latest approval for the fourth-generation MitraClip device, MitraClip G4, puts new enhancements into the hands of physicians across the U.S. by delivering an expanded range of clip sizes, an alternative leaflet grasping feature and facilitation of procedure assessment in real time to offer doctors further options when treating mitral valve disease.
The MitraClip device repairs leaky mitral valves without open-heart surgery and is delivered to the heart through a small incision in the leg. The device clips portions of the leaflets, or flaps, of the mitral valve together to reduce the backflow of blood, known as mitral regurgitation (MR). This restores the heart's ability to pump oxygenated blood more efficiently.
Abbott has expanded MitraClip to a total of four clip sizes – now including clips with wider grasping area – to provide physicians additional options for treatment. MitraClip G4 also offers independently controlled grippers that allow physicians to grasp one or both leaflets during the procedure, known as Controlled Gripper Actuation.
In addition to four clip sizes and the leaflet grasping feature, the latest generation of MitraClip offers the benefit of an upgraded catheter to allow integrated real-time continuous left atrial pressure monitoring during implant. The feature allows physicians to use a commercially available pressure monitor integrated into the MitraClip catheter to continuously monitor and confirm MR reduction during the implant procedure. This helps them determine whether the MitraClip should be repositioned or placed differently to optimize patient outcomes.
For more information: abbott.com
November 03, 2026 
